Valley Forge Investment Consultants Inc. ADV Purchases Shares of 83,225 ARS Pharmaceuticals, Inc. $SPRY

Valley Forge Investment Consultants Inc. ADV acquired a new stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 83,225 shares of the company’s stock, valued at approximately $667,000. ARS Pharmaceuticals accounts for 0.2% of Valley Forge Investment Consultants Inc. ADV’s holdings, making the stock its 18th biggest holding. Valley Forge Investment Consultants Inc. ADV owned 0.08% of ARS Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in SPRY. BlackRock Inc. purchased a new stake in shares of ARS Pharmaceuticals during the second quarter worth approximately $42,544,000. Rubric Capital Management LP grew its holdings in ARS Pharmaceuticals by 247.5% during the 3rd quarter. Rubric Capital Management LP now owns 4,500,000 shares of the company’s stock worth $45,225,000 after acquiring an additional 3,205,122 shares in the last quarter. Millennium Management LLC acquired a new position in ARS Pharmaceuticals during the 4th quarter worth approximately $36,912,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of ARS Pharmaceuticals in the 2nd quarter valued at approximately $30,154,000. Finally, UBS Group AG increased its position in shares of ARS Pharmaceuticals by 235.0% in the 4th quarter. UBS Group AG now owns 2,210,866 shares of the company’s stock valued at $25,757,000 after purchasing an additional 1,550,980 shares during the last quarter. 68.16% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at ARS Pharmaceuticals

In related news, insider Alexander A. Fitzpatrick sold 3,355 shares of ARS Pharmaceuticals stock in a transaction on Friday, June 12th. The shares were sold at an average price of $10.00, for a total transaction of $33,550.00. Following the sale, the insider directly owned 90,910 shares in the company, valued at $909,100. This trade represents a 3.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Eric Karas sold 25,000 shares of the business’s stock in a transaction on Friday, June 12th. The shares were sold at an average price of $10.00, for a total transaction of $250,000.00. Following the completion of the sale, the insider directly owned 12,176 shares of the company’s stock, valued at approximately $121,760. This trade represents a 67.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 33.80% of the company’s stock.

ARS Pharmaceuticals Stock Performance

Shares of SPRY opened at $6.30 on Wednesday. The stock has a 50 day moving average price of $7.46 and a 200 day moving average price of $8.23. The company has a quick ratio of 3.28, a current ratio of 3.48 and a debt-to-equity ratio of 13.72. The company has a market capitalization of $625.61 million, a price-to-earnings ratio of -2.89 and a beta of 0.98. ARS Pharmaceuticals, Inc. has a 52-week low of $4.91 and a 52-week high of $15.09.

ARS Pharmaceuticals (NASDAQ:SPRY) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.15). ARS Pharmaceuticals had a negative return on equity of 256.67% and a negative net margin of 184.24%.The company had revenue of $33.66 million for the quarter, compared to analyst estimates of $31.32 million. Research analysts predict that ARS Pharmaceuticals, Inc. will post -1.9 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on SPRY shares. Cantor Fitzgerald raised their price objective on shares of ARS Pharmaceuticals from $12.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, May 28th. Weiss Ratings downgraded shares of ARS Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday. Leerink Partners dropped their target price on ARS Pharmaceuticals from $25.00 to $24.00 and set an “outperform” rating on the stock in a report on Thursday, June 25th. Finally, Wall Street Zen upgraded ARS Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $28.20.

Key Stories Impacting ARS Pharmaceuticals

Here are the key news stories impacting ARS Pharmaceuticals this week:

• Positive Sentiment: Some analysts remain constructive on ARS Pharmaceuticals. A Seeking Alpha analysis argues that the new CEO’s cost-reduction initiatives and efforts to increase revenue could improve the company’s outlook. ARS Pharma: New CEO’s Program Of Reducing Costs While Increasing Revenues Makes A Buy
• Neutral Sentiment: Brokerage coverage cited in a separate report gives ARS Pharmaceuticals an average “Moderate Buy” rating, suggesting some analysts still see value despite recent execution and legal concerns. ARS Pharmaceuticals Given Average Rating of Moderate Buy by Brokerages
• Negative Sentiment: Several law firms, including Pomerantz, SBS Law, Gross Law Firm, Faruqi & Faruqi, Robbins and Rosen, are soliciting investors for a securities-fraud class action covering purchases from March 9 through June 24, 2026. The filings allege ARS did not adequately disclose that expanded CVS Caremark formulary coverage for neffy, expected to become effective July 1, 2026, could be delayed until January 2027. Pomerantz Investor Alert
• Negative Sentiment: The allegations claim shareholders suffered losses after the anticipated CVS coverage decision did not occur, with one notice citing an estimated $2.52 per-share decline. The claims remain allegations, and ARS Pharmaceuticals’ ultimate legal and financial exposure has not been established. Levi & Korsinsky Investor Alert
• Negative Sentiment: Investors have until October 5, 2026 to seek appointment as lead plaintiff. The unusually large number of law-firm notices amplifies visibility around the dispute and adds an overhang to SPRY shares.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.